At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 140 enrolled

Drug / intervention

Argatroban +3 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00508924

NCT00508924Phase 2Completed

Compare CT.gov

A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin

Tanabe Pharma Corporation·interventional·Posted Jul 30, 2007·Updated Jan 6, 2026

In Brief

A Phase 2 clinical trial evaluating Argatroban and Heparin for Coronary Artery Disease and Angina, Unstable. Completed, enrolled 140 participants across 8 sites in 2 countries.

Detailed Summary

This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in combination with dual antiplatelet therapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCoronary Artery Disease, Angina, Unstable

CountriesBelgium, Germany

Collaborators--

Timeline

Phase 2CompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartAug 2005

Study CompletionOct 2006

First PostedJul 2007

TodayJul 2026

First PostedJul 30, 2007

Enrollment StartAug 1, 2005

Study CompletionOct 1, 2006

TodayJul 2, 2026

Posted 18.9 years ago

Interventions

Argatrobandrug

Heparindrug